Dr. Mika Kontro will discuss the methods for personalizing AML therapies using functional screening. He will provide an overview of the current data implementation and share insights from ongoing prospective trials employing functional screening. Furthermore, Dr. Kontro will focus on the VenEx trial, which utilizes ex vivo drug sensitivity testing to identify AML patients who can benefit from the azacitidine-venetoclax regimen.

More info can be found on this link.

Join via Zoom using this link.

No registration necessary.